HRT Hormone Replacement Therapy
HRT Hormone Replacement Therapy


I have had a DVT or pulmonary embolism. Can I take HRT?

Home
What's New - Blog
Abortion
Amenorrhoea - Absent Periods
Birth Control
Bladder Symptoms
Cancer in Women
Diet / Weight Loss
Dysmenorrhoea
Ectopic Pregnancy
Endometriosis
Female Sexual Problems
Fibroids
HRT Risks & Benefits
Hysterectomy
Infections
Infertility
Medication - Drugs
Menopause
Menorrhagia Heavy Periods
Miscarriage
Painful Sex - Dyspareunia
Pap Smear Test
PCOS
Pelvic Pain
PMS- Premenstrual Syndrome
Pregnancy & Childbirth
Vaginal Discharge
Vaginal Prolapse
Viagra, Libido and Sex Drive.
The Author
Consultations
Contact Us

Obstet Gynecol. 2008 Feb;111(2):278-284.

Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers: A Randomized Controlled Trial.
Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M.

Department of Obstetrics and Gynecology, Department of Medical Biostatistics, and the Division of Hematology Oncology, Department of Medicine, University of Vermont, Burlington, Vermont; and Department of Biochemistry, Maastricht University, Maastricht, the Netherlands.

Objectives:

To compare the effects of oral and transdermal contraceptives containing similar hormone formulations on vascular risk markers.

Methods:

We conducted a randomized, investigator-blinded, crossover, clinical trial with 24 healthy women, aged 18-35 years, who received 2 months of transdermal or oral contraceptive, 2 months washout, then 2 months of the alternative medication. The transdermal contraceptive contained 0.75 mg ethinyl estradiol and 6 mg norelgestromin. The oral contraceptive contained 35 mcg ethinyl estradiol and 250 mcg norgestimate. Blood samples taken before and after each treatment were analyzed in batch for D-dimer, von Willebrand factor, factor VIII, total and free protein S, antithrombin, fibrinogen, C-reactive protein, and normalized activated protein C sensitivity ratio (nAPCsr) determined with two thrombin generation-based assays, the alpha2macroglobulin-thrombin end point method (alpha2M-IIa) and calibrated automated thrombinography. Repeated measures analysis of variance was used for analysis.

Results:

For both contraceptives (transdermal, oral) there were significant declines in free (19%, 11%) and total protein S (19%, 13%) and antithrombin (13%, 10%); increases in fibrinogen (8%, 10%), C-reactive protein (220%, 292%), nAPCsr alpha2M-IIa (81%, 61%), and nAPCsr calibrated automated thrombinography (102%, 68%), all P<.05. Transdermal contraceptives had a greater effect than oral contraceptives on free protein S (P=.07), nAPCsr alpha2M-IIa (P=.06), and nAPCsr calibrated automated thrombinography (P=.03).

Conclusion:

Oral and transdermal contraception with similar hormones had similar adverse effects on vascular risk markers. This suggests that this transdermal contraceptive has at least a similar thrombosis risk as its oral counterpart.


Back Home Up

Please click on the required question.

Do you have an unanswered women's health question?

Please let us have your general question on our NEW FORUM / MESSAGE BOARDS facility and we will try to answer it for you. I am sure that you will appreciate that we cannot offer advice on the management of an individual's specific problem.


Thank you for your visiting us at 2WomensHealth.com.

This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London.

I do hope that you find the answers to your questions in the patient information and medical advice provided. If you still have unanswered questions, please consider entering them into one of our forums and I will try to assist you.

DISCLAIMER

The aim of this web site is to provide a general guide and it is not intended as a substitute for a consultation with an appropriate specialist in respect of individual care and treatment.